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1. Introduction
Heart failure is a growing worldwide phenomenon, affecting more than 10 million people
between the U.S. and Europe [1]. The quality of life for advanced heart failure patients is poor,
with repeat hospitalizations and high rates of mortality. With the aging of the general popu‐
lation the number of people experiencing heart failure will rise. Cardiac transplantation has
been the goal for some patients, but the growth in number of available donors has not kept
pace with the number of potential recipients, and optimal candidates are carefully selected.
As a result the search for alternative therapies to support a failing heart, in particular the
development of ventricular assist devices (VAD) has been a focus of research for more than 30
years.
Because refractory heart failure frequently involves failure of the dominant left ventricle, early
devices were designed to assume the work of the left ventricle. The intent was to improve
overall blood flow to the body and organs, reducing some symptoms and secondary end organ
failure. Early devices were used primarily as a bridge to transplantation (BTT) to assist patients
waiting for a suitable organ. The technology has continued to advance over the last decade
and many such devices are in use as stand alone, or destination therapy. The use of VADs has
been associated with immune dysregulation and allosensitization, which can be an impedi‐
ment to transplantation.
This chapter will review the evolution of assist devices in relation to alloimmunity, specifically
antibodies to human leukocyte antigens (HLA). The development of antibodies to HLA
antigens is caused by exposure via pregnancy, transplantation, and blood transfusion. The
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level and specificity of alloantibodies is detected by screening against a panel of typed cells or
antigen bound to a solid surface, and is reported as panel/percent reactive antibodies (PRA).
Different test methods have yield different sensitivity with cell-based (complement dependent
cytotoxicity; CDC) being least sensitive and solid phase being most sensitive.
2. Role of alloantibody in acute rejection and chronic allograft
vasculopathy
The rapid evolution of effective immunosuppressant drugs has significantly decreased the
frequency and severity of acute cellular rejection following cardiac transplantation, but the
incidence and effective treatment of antibody mediated rejection (AMR), especially over the
long term remains problematic. AMR was first described in 1987 by Herskowitz [2] as arteriolar
vasculitis associated with poor outcome. Patients at increased risk are multiparous women
and patients with alloantibody against donor antigens detected both pre- and post-transplant.
Diagnosis requires clinical graft dysfunction, pathological evidence (endothelial swelling,
presence of C4d positive staining on biopsy), and detectable donor specific antibody. Available
treatments include plasmapheresis, intravenous steroids, intravenous immunoglobulin, and
monoclonal antibodies directed against antibody producing cells (e.g. Rituximab targets
CD20).
Acute AMR with high titer antibody damages graft tissue by activation and fixation of
complement. The cascade induces coagulation and the terminal event results in the membrane
attack complex which injures vascular endothelium. Severe AMR can result in death. Lower
titer alloantibody associated with chronic AMR activates endothelial intracellular signaling
cascades [3] inducing cell proliferation manifested ultimately as transplant vasculopathy and
deterioration of graft function. Ho [4] recently reported results of a large cohort (n=950) of
transplants with long term follow-up including biopsies and HLA antibody testing. Develop‐
ment of AMR had significant impact on long term graft survival (16% versus 63% in the AMR
negative group at 12 years). In most cases the recipient demonstrated antibody directed against
donor HLA antigens. Importantly those who developed antibody more than one year after
transplant had the worst outcomes.
Since recipients who demonstrate pretransplant anti-HLA antibodies have higher risk of graft
dysfunction, preventing allosensitization is important. However, the use of ventricular assist
devices has a history of association with high alloantibody titer. Minimizing the incidence of
antibody induction is of prime importance. Table 1 summarizes existing literature of allosen‐
sitization among VAD implanted patients. There is a trend toward decreasing allosensitization
over time, concurrent with evolution of device from pulsatile to axial flow, evolution of
antibody testing from cell-based to solid phase, and an increasing use of leukoreduced blood
products.
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Author Study period Center Device n=
PRA>10% 
(method) % male Blood modification
Massad, M et al 
1997 1992-1995 Cleveland
HeartMate 
pulsatile 53 65% (CDC) 87.0% Few leukoreduced
John R et al, 2003 1992-99 New York HeartMate pulsatile 105 66% (CDC) 78.1% Not reported
Drakos, S et al 
2007 1993-2002 Utah
HeartMate 
pulsatile 71 53.7% (CDC) 91.5%
Lower among 
leukofiltered
McKenna D, et al 
2002 1995-2000 Minneapolis not reported 29 28% 83.0% Few leukofiltered
Pagani F et al 
2000 1996-2000 Michigan
HeartMate 
pulsatile 38 28% (CDC) 67.6% Most leukofiltered
George I, et al 
2008 1999-2006 New York
HeartMate 
pulsatile 36 28% (CDC) 83.0% Most leukofiltered
Arnaoutakis, et al 
2011 2004-2009 UNOS HM XVE pulsatile 673 25.3% (multiple) 84.8% Not reported
Kumpati, G et al 
2004 1991-2000 Cleveland
HM/Novacor 
pulsatile 231 <5% (CDC) 84.0% Filtration >1995
Baran, D et al 
2005 1989-2002 New Jersey Novacor pulsatile 26 27% (CDC) 96.2% Not reported
Kirsch, L et al 
2007 1985-2006 Brussels Novacor pulsatile 27 18.5% (CDC) 65.5% Not reported
George I, et al 
2008 1999-2006 New York
HeartMate II/
DeBakey 24 8% (CDC) 83.0% Most leukofiltered
Grinda, J et al 
2005 199-2004 Paris DeBakey- axial 14 0% CDC/ELISA 100.0% All leukoreduced
Drakos, S et al 
2009 not reported Utah HeartMate II axial 11
9% (CDC/bead 
array) 63.6% Most leukofiltered
Coppage, M et al 2009 New York Mixed multiple 55 8% (CDC/bead array) 85.0% All leukoreduced
Table 1. Literature on allosensitization among recipients of assist devices.
3. Volume displacement pumps
Early devices were designed to mimic the pulsatile flow of a native heart [5]. These devices
include the Thoratec “HeartMate I XVE/1P” and the Abiomed “BVS5000/AB5000.” Due to the
mechanical nature of these devices reliability was an issue. This first generation of pumps had
large surface area that contacted both tissue and blood, and were associated with multiple
reports of coagulopathy, immune dysregulation, and allosensitization. In 1997 Massad [6]
reported that LVAD (HeartMate) patients were at increased risk for development of antibodies
to HLA. While less than 5% of the 53 patients observed had PRA greater than 10% as measured
in the CDC assay prior to VAD placement, 66% developed antibody after receiving a VAD.
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The overall mean PRA increased significantly from 2.1% to 33.5% during VAD support,
although a decrease was observed over time. One source of sensitization to HLA antigens is
transfusion, and this group also reported an average of 148 units of blood products on the
HeartMate, although the association was limited to transfusion associated with the LVAD and
not remote blood product support. During the next few years, other groups also reported that
VAD implantation was associated with allosensitization [7-9].
In contrast Stringham [10] reported on a small population (n=6) of recipients who survived
VAD implantation without transfusion of blood or platelets. Three of the patients had no
history of and did not develop anti-HLA antibody up to transplantation at days 33-50. The
other three patients all became highly sensitized with PRA >90% between 30 and 90 days after
the VAD surgery. They speculate three potential causes. First, all of the patients did receive
fresh frozen plasma (FFP) after separation from the cardiopulmonary bypass, and FFP may
contain soluble HLA antigens. Second, two of the three had experienced previous cardiac
surgery accompanied by transfusion. They argue that the cardiac dysfunction leading up to
VAD placement may have induced a state of immune anergy that was broken when improved
cardiac function was restored. This association is not supported by the previously reported
Massad[6] study that demonstrated no correlation between remote cardiac surgery with
transfusion and later sensitization. Finally, they postulate that immunogenic component(s) of
the LVAD cause development of antibody directed against or cross-reactive with HLA
antigens. The same group [11] later presented a larger cohort of HeartMate recipient (n=71)
analyzing the effect of leuko-reduced blood products, but found no significant effect. Our
laboratory [12] reported a series of 55 VAD recipients, most of whom had received a pulsatile
device. Our center only uses leuko-reduced, irradiated, and ABO matched blood products and
we observed minimal allosensitization.
Drakos [13] undertook a study to determine risk factors contributing to allosensitization. They
reviewed records of 75 patients, most of whom received the HeartMate I. The most significant
factor identified was a history of prior sensitization to HLA antigens, followed by female
gender. Neither of these findings is surprising. Pregnancy is a common sensitizing event, and
the presence of HLA allosensitization predisposes to increased antibody production upon re-
exposure to antigen. This same group [14] investigated the use of prophylactic intravenous
immunoglobulin, commonly used in desensitization strategies, in prevention of HLA sensiti‐
zation. Patients received either no IVIG or 10g per day of IVIG for 3 days after VAD implan‐
tation. The groups were of equal size (25 and 26 respectively), but were not randomized. No
statistically significant difference in PRA was observed between the groups, and the overall
rate of sensitization (defined as PRA >10%) was over 30% for both.
Several reports addressed the issue of allosensitization stratified by the type of device. The
early reports compared the pulsatile pumps with one another. Baran [15] assessed sensitization
in a series of 23 patients who received the Novacor (Worldheart, Ottawa) device prior to
transplant as opposed to the HeartMate for which previous high PRA had been reported. They
note that the HeartMate I was made of textured titanium that develops a neointimal lining that
averts the need for systemic anti-coagulation. However, the existence of this lining was
suggested to induce immune up-regulation associated with increased PRA. The Novacor had
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a smooth blood-contacting surface that would not develop a neointimal lining. Of the 23
patients, 13 had less than 5% change in PRA, five had increases of up to 30%, and five experi‐
enced a decrease in PRA as tested in the CDC assay. Post-transplant courses were not signif‐
icantly different between the BTT and non-BTT groups with similar rates of rejection and
transplant vasculopathy. Another group [16] undertook a propensity matched study of 231
patients who received either the HeartMate I (n=166) or Novacor (n=55) device. In contrast to
Baran [15], this group observed no differential rate of sensitization in a much larger patient
population. However, they did report a general rapid, but small increase in PRA in the
immediate post-VAD implantation period that decreased over time. In this study, the predic‐
tors of sensitization include female sex (pregnancy is a common source of allosensitization)
and total number of blood transfusions. The overall level of sensitization of this population
was lower than previous reports, with peak PRA <50%, possibly due to their predominant use
of leukoreduced blood products.
Gonzalez-Stawinski [17] reviewed early and late rejection as well as HLA sensitization in a
series of 119 recipients who were bridged to transplant with 3 different types of VAD, but all
were volume displacement. Not surprisingly, higher PRA and positive flow cytometry
crossmatch was associated with increased level of rejection on biopsy at 30 days and 2 years
post-transplant, but long term outcome was not addressed. However, Joyce [18] surveyed the
International Society of Heart and Lung Transplant (ISHLT) registry and divided the cardiac
transplant group (n=11,457) into 3 groups including LVAD used, not used, or unknown.
Virtually all of the VAD recipients receive pulsatile devices. In this large dataset, the presence
of VAD was a significantly higher (p<0.0001) predictor of sensitization as defined by PRA>10%.
Importantly, rates of rejection, measured by comparing drug treated events from transplant
to 1 year follow up were not different between recipients who bridged with a VAD and those
who did not. Likewise there were no significant differences in mortality at 1 or 2 years between
the groups.
4. Axial flow pumps
The second generations of assist devices are smaller and contain an impeller that spins to
deliver blood through the circulatory system [5]. These pumps are much smaller in size, but
the impeller moves at 6000 rpm to 15000 rpm, which may cause hemolysis and platelet
activation contributing to general immune activation.
Grinda[19] reported Anti-HLA sensitization for a group of 21 patients who were implanted
with the DeBakey axial flow VAD. For this study PRA was measured by both the CDC and
solid phase assays. None of their patients developed detectable anti-HLA antibodies during
the course of VAD support with mean duration 87 days (range 21-224). This group also uses
only leukoreduced blood products. Their findings were supported by a later report from
George[20] who compared sensitization observed among patients who received one of two
axial flow devices (HeartMate II and DeBakey n=24) with the pulsatile (HeartMate I n=36)
device. Alloantibody was tested in all patients by the CDC method, and sensitization was
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defined as a PRA of >10%. The actual percent PRA was not reported. They observed a
significantly higher rate of sensitization for recipients of the HeartMate I pulsatile device (28%)
compared with either axial device (8% p<0.01). In both groups the number of allosensitized
decreased over time and was lower at the time of heart transplant than as measured after VAD
placement. The presence of sensitization did not affect short-term survival in either the axial
or pulsatile group.
5. Radial flow devices
The third generation of VADs provides radial or centrifugal flow. In general, they are slightly
larger than the axial flow devices, but their design makes them especially suited to long term
cardiac support. For that reason these devices are ideal for use as a destination or permanent
therapy. Allosensitization would therefore not be an impediment to future therapy. There is
one report [21] of successful cardiac transplantation of a small cohort of recipients who had
been implanted with HeartWare (Heartware International, USA) or VentriAssist (Ventracor,
Ltd, Australia) centrifugal devices. Thirteen patients were transplanted with a one year
survival of 91%. While no allosensitization or crossmatch data are presented, one may infer
that alloantibody was not a obstruction to transplantation. Conversely, there is a report [22]
regarding the Evaheart (Medical USA, Inc) that demonstrates significant platelet activation
using centrifugal VAD and two different coatings (carbon versus 2-methoxyethyloylphos‐
phoryl choline) in a bovine model. While platelet activation does not itself lead to allosensiti‐
zation, platelet activation and microaggreagates were also associated with coagulopathy and
ultimately allosensitization in some of the earlier models. As of this writing, no specific reports
of anti-HLA antibody associated with the use of radial flow VADs exist.
6. Immune dysregulation associated with VADs
The development of ventricular assist devices provided extended time for patients who were
waiting for a compatible heart to become available. The theory and technology has steadily
improved over the last 2 decades. Devices are smaller and have a reduced contact with the
body’s blood and tissue, thus making them less immunogenic. This fact is reflected in the data
reviewed here. In the late 1990s and early 2000s, the pulsatile devices were most common, and
reports documenting the risk of allosensitization stem from VADs began during this period.
The relatively large surface area and composition of materials made for greater contact with
tissue and blood, and in addition to reports of allosensitization came reports of general immune
dysregulation [23, 24] and coagulopathy [25, 26].
Recipients of the early smooth textured VADs were at increased risk for hemorrhage and later
for thromboembolism [27, 28]. Later devices incorporated a textured surface on which
developed a neointimal cellular lining. Although the risk of thromboembolic events declined,
the cellular lining introduced new complications. These cells were demonstrated to be
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primarily resting monocytes and activated macrophages[23]. These cells help to maintain an
inflammatory state, and were shown to augment production of cytokines (especially of TH2
pathway) and coagulation factors [23]. John [29] studied markers of endothelial and coagula‐
tive activation in 21 LVAD recipients (HeartMate II) and noted significant baseline activation
of both systems in the immediate postoperative period, with elevated levels remaining to 180
days. Rothenburger [30] also demonstrated that T and NK cell populations decreased and the
level remained depressed for over 100 days. At the same time B cell numbers increased as did
IL-6 and CRP. Hyper-reactivity of B cells was postulated as VAD recipients demonstrated
elevated antiphospholipid antibodies in addition to the risk of anti-HLA antibodies. A more
recent study [31] demonstrated the presence of natural antibodies in transplant candidates
with VAD. Taken as whole, cardiopulmonary bypass surgery and implantation of a ventricular
assist device induces systemic inflammation and humoral amplification[32] including
coagulation and complement cascades.
Not surprising given immune dysregulation and the introduction of a foreign body, infection
is a nearly universal threat for device-related morbidity. The literature for infectious compli‐
cations is extensive and will not be reviewed here. The presence of microorganism(s) or fungi,
however, contributes to humoral amplification.
7. Immunomodulatory effects of transfused blood products
Our group has observed that soluble immune modulatory factors (sCD40L, IL-8, and RANTES)
are present and biologically active in platelet concentrates [33-35] and non-leukoreduced red
cells, and to a lesser extent this may be true of FFP as well. We hypothesize that intravenously
administered blood components (including FFP), administered as a bolus (as opposed to being
produced in a paracrine manner) access the lymphatic system where immune effectors reside,
and modulate their responses. This complements previously reported systemic alterations and
immune dysregulation involving B cells following VAD implantation [23, 30, 36]. Prior to the
general acceptance of universal leukoreduction, a prime indication of this effect on B cell
immunity was the production of anti-HLA antibodies. MHC molecules are immunogenic and
provide a stimulus for an antibody response. Anti-HLA responses became a focus regarding
the hazards of blood transfusion in VAD patients. Immunomodulatory factors present in blood
transfusion, especially those that contain white cells or platelets, contribute to a systemic TH2
response, including non-specific activation of B cells and up-regulation of immunoglobulin
production [37].
8. Evolution of antibody testing systems
As the technology and understanding of device technology has evolved over the years, so has
the science of histocompatibility testing. The practice standard until the last decade was the
complement dependent cytotoxicity (CDC) test, often augmented by anti-human globulin
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(AHG) to detect low levels of or non-complement fixing antibody. Most of the early reports
describe the use of some form of CDC assay, but the addition or exclusion of AHG impacts the
sensitivity and specificity of the test. It may allow identification of low level alloantibody, but
is also more prone to false positive detection. In the late 1990s, solid-phase assay began to be
adapted. The first generation was enzyme-linked immunosorbent assays (ELISA). ELISA
assays include HLA antigen bound to a solid, generally plastic surface. These tests are more
sensitive than cell based assay, and also include the use of AHG. Newell[38] reported that IgG
antibodies detected in the ELISA assay of serum from VAD patients were actually anti-albumin
antibodies, a reagent commonly used in ELISA assays. The positive reactions converted to
negative when sera were pre-incubated with albumin-coated beads. Similarly, serum from
VAD patients tested in our laboratory [12] exhibited reactivity in ELISA assays, but reactivity
occurs even in wells that do not contain HLA antigen, indicating false positive reactions.
The up-regulation of humoral immunity described for VAD recipients may include specific
(e.g. anti-albumin), non-specific (e.g. natural anti-ABO), and memory (e.g. anti-HLA from
pregnancy) antibody responses. Our group has also reported the formation of circulating
immune complexes of ABO antigen and their corresponding antibodies in patients who
received ABO unmatched platelets [39, 40]. We believe that any or all of these phenomena may
interfere with immune assays, especially those that use an anti-immunoglobulin (second-step)
reagent such as ELISA, and flow or AHG crossmatch. Recently, however, bead based anti-HLA
antibody tests were introduced. In our hands these have proved to be both sensitive and
specific, although, like other solid-phase assays they use an anti-human immunoglobulin
secondary step. The beads used in these assays are particulate in nature and more rigorous
wash steps to remove low avidity antibody may be used to limit weak or non-specific reactions.
However, some kits employ recombinant HLA antigen that has an increased propensity for
denaturing due to alternate glycosylation and peptide loading. There are multiple reports of
“natural” antibody that reacts with HLA antigen [41, 42] and also to denatured HLA antigens
[43] that have little or no clinical relevance to allotransplantation. Awareness of the strengths
and weaknesses of the various assays that are employed in determining anti-HLA sensitization
is vital to accurate interpretation of the data they provide.
A final confounding factor in assessing the role of anti-HLA antibody in ventricular assist
devices is how allosensitization is defined. Much of the cardiothoracic literature defines
allosensitized as having a PRA > 10%, meaning the candidate has antibody against 10% of the
HLA antigens expected among the local organ donor pool. Conversely, this means that the
candidate does NOT have antibody to 90% of HLA antigens, and has a 90% likelihood of
finding a compatible donor. The histocompatibility community generally does not consider a
person highly sensitized unless they demonstrate antibody against more than half of a
standard panel. Thus centers who reported rates of sensitization of 30-60% may have simply
been using a definition that encompasses patients who should not be so classified. In this light
the phenomenon of allosensitization might not exist under a more stringent definition.
In summary, the introduction of a foreign device via major cardiopulmonary bypass surgery
is not an immunologically benign event. Patients have systemic complications going into the
surgery secondary to cardiac failure. Some of these improve with the introduction of the VAD
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and improved blood circulation, but inflammation, infection, and coagulopathy are consistent
causes of morbidity and mortality in this population. Continued improvements of the devices
to those that are smaller and have continuous flow are less invasive and are more reliable for
long term use. Literature around use of the early, large, pulsatile devices pointed to allosen‐
sitization to HLA antigens as posing an impediment to using the VAD as a bridge to trans‐
plantation. Over the years, our understanding of immune events and the systems used to tests
for allosensitization have also evolved. In addition many centers have implemented policies
for using leukoreduced blood products. While the development of anti-HLA antibodies is a
clear risk for some recipients (e.g. multiparous women, previous sensitized recipients), the
phenomenon is not as widespread as once assumed.
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